|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 340.00 EUR | +0.44% |
|
-0.44% | -4.90% |
| 29/07 | Virbac, without the alibi |  |
| 21/07 | Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Veterinary Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 327.43Cr | |||||
| 3.12TCr | |||||
| 1.31TCr | |||||
| 385.47Cr | |||||
| 213.65Cr | - | - | |||
| 190.23Cr |
- Stock Market
- Stocks
- VIRP Stock
- Charts Virbac
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
